Parabilis Medicines, Inc.
PBLS
$38.76
-$1.01-2.54%
NASDAQ
| 06/30/2026 | 03/31/2026 | 06/30/2025 | |||
|---|---|---|---|---|---|
| Net Income | -52.46M | -45.32M | -34.81M | ||
| Total Depreciation and Amortization | 593.00K | 606.00K | 618.00K | ||
| Total Amortization of Deferred Charges | -- | -- | -- | ||
| Total Other Non-Cash Items | 10.73M | 3.04M | 2.73M | ||
| Change in Net Operating Assets | 37.52M | -7.53M | 370.00K | ||
| Cash from Operations | -3.62M | -49.20M | -31.09M | ||
| Capital Expenditure | -616.00K | -369.00K | -16.00K | ||
| Sale of Property, Plant, and Equipment | -- | -- | -- | ||
| Cash Acquisitions | -- | -- | -- | ||
| Divestitures | -- | -- | -- | ||
| Other Investing Activities | -33.45M | -- | 24.53M | ||
| Cash from Investing | -34.06M | -369.00K | 24.51M | ||
| Total Debt Issued | -- | -- | -- | ||
| Total Debt Repaid | -3.91M | -3.90M | -144.00K | ||
| Issuance of Common Stock | 802.16M | 187.00K | 9.00K | ||
| Repurchase of Common Stock | -- | -- | -- | ||
| Issuance of Preferred Stock | 0.00 | 305.25M | 0.00 | ||
| Repurchase of Preferred Stock | -- | -- | -- | ||
| Total Dividends Paid | -- | -- | -- | ||
| Other Financing Activities | -2.54M | 49.37M | 0.00 | ||
| Cash from Financing | 795.71M | 350.90M | -135.00K | ||
| Foreign Exchange rate Adjustments | -- | -- | -- | ||
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | ||
| Net Change in Cash | 758.02M | 301.33M | -6.71M | ||